Broad selective efficacy of recombinant methioninase and polyethylene glycol-modified recombinant methioninase on cancer cells in vitro

Anticancer Research

Volumn 30, Issue 4, 2010, Pages 1041-1046

  Tan, Yuying ^a   Xu, Mingxu ^a   Hoffman, Robert M ^a,b  

^a ANTICANCER INC   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cancer; Efficacy; Methioninase; Methionine dependence; PEG methioninase; PEG rMETase; rMETase; Selectivity

Indexed keywords

MACROGOL; RECOMBINANT METHIONINE GAMMA LYASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IC 50; IMMUNOGENICITY; IN VITRO STUDY; KERATINOCYTE; KIDNEY CANCER; LUNG ALVEOLUS EPITHELIUM; LUNG CANCER; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PSEUDOMONAS PUTIDA; SKIN FIBROBLAST;

ANTIMETABOLITES, ANTINEOPLASTIC; CARBON-SULFUR LYASES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

EID: 77953801590     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Mecham JO, Rowitch D, Wallace CD, Stern PH and Hoffman RM: The metabolic defect of methionine dependence occurs frequently in human tumor cell lines. Biochem Biophys Res Commun 117: 429-434, 1983. (Pubitemid 14177577)
2. Hoffman RM and Erbe RW: High in vivo rates of methionine biosynthesis in transformed human and malignant rat cells auxotrophic for methionine. Proc Natl Acad Sci USA 73: 1523-1527, 1976.
3. Stern PH and Hoffman RM: Enhanced in vitro selective toxicity of chemotherapeutic agents for human cancer cells based on a metabolic defect. J Nad Cancer Inst 76: 629-639, 1986.
4. Hoffman RM: Altered methionine metabolism, DNA methylation and oncogene expression in carcinogenesis: a review and synthesis. Biochim Biophys Acta Reviews on Cancer 738: 49-87, 1984.
5. Tisdale MJ: Utilization of preformed and endogenously synthesized methionine by cells in tissue culture. Br J Cancer 49: 315-320, 1984.
6. Halpern BC, Clark BR, Hardy DN, Halpern RM and Smith RA: The effect of replacement of methionine by homocystine on survival of malignant and normal adult mammalian cells in culture. Proc Natl Acad Sci USA 71: 1133-1136, 1974.
7. Tisdale M and Eridani S: Methionine requirement of normal and leukaemic haemopoietic cells in short term cultures. Leuk Res 5: 385-394, 1981.
8. Guo HY, Herrera H, Groce A and Hoffman RM: Expression of the biochemical defect of methionine dependence in fresh patient tumors in primary histoculture. Cancer Res 53: 2479-2483, 1993. (Pubitemid 23168009)
9. Breillout F, Hadida F, Echinard-Garin P, Lascaux V and Poupon MF: Decreased rat rhabdomyosarcoma pulmonary metastases in response to a low methionine diet. Anticancer Res 7: 861-867, 1987.
10. Poirson-Bichat F, Gonfalone G, Bras-Gonçalves RA, Dutrillaux B and Poupon MF: Growth of methionine-dependent human prostate cancer (PC-3) is inhibited by ethionine combined with methionine starvation. Br J Cancer 75: 1605-1612, 1997. (Pubitemid 27229050)
11. Guo H, Lishko VK, Herrera H, Groce A, Kubota T and Hoffman RM: Therapeutic tumor-specific cell cycle block induced by methionine starvation in vivo. Cancer Res 53: 5676-5679, 1993.
12. Breillout F, Antoine E and Poupon MF: Methionine dependency of malignant tumors: a possible approach for therapy. J Natl Cancer Inst 82: 1628-1632, 1990. (Pubitemid 20345300)
13. Poirson-Bichat F, Lopez R, Bras Concalves RA, Miccoli L, Bourgeois Y, Demerseman P, Poisson M, Dutrillaux B and Poupon MF: Methionine deprivation and methionine analogs inhibit cell proliferation and growth of human xenografted gliomas. Life Sci 60: 919-931, 1997.
14. Goseki N, Yamazaki S, Shimojyu K, Kando F, Maruyama M, Endo M, Koike M and Takahashi H: Synergistic effect of methionine-depleting total parenteral nutrition with 5-fluorouracil on human gastric cancer: a randomized, prospective clinical trial. Jpn J Cancer Res 86: 484-489, 1995.
15. Sugimura T, Birnbaum SM, Winitz M and Greenstein JP: Quantitative nutritional studies with water-soluble, chemically defined diets. VIII. The forced feeding of diets each lacking in one essential amino acid. Arch Biochem Biophys 81: 448-455, 1959.
16. Epner DE, Morrow S, Wilcox M and Houghton JL: Nutrient intake and nutritional indexes in adults with metastatic cancer on a Phase I clinical trial of dietary methionine restriction. Nutrition and Cancer 42: 158-166, 2002. (Pubitemid 35253663)
17. Hoshiya T, Kubota T, Inada T, Kitajima M and Hoffman RM: Methionine-depletion modulates the efficacy of 5-fluorouracil on human gastric cancer in nude mice. Anticancer Res 17: 4371-4376, 1997. (Pubitemid 28081714)
18. Goseki N and Endo M: Thiol depletion and chemosensitization on nimustine hydrochloride by methionine-depleting total parenteral nutrition. Tohoku J Exp Med 161: 227-239, 1990. (Pubitemid 20379797)
19. Yoshioka T, Wada T, Uchida N, Maki H, Yoshida H, Ide N, Kasai H, Hojo K, Shono K, Maekawa R, Yagi S, Hoffman RM and Sugita K: Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase. Cancer Res 58: 2583-2587, 1998.
20. Machover D, Zittoun J, Broet P, Metzger G, Orrico M, Goldschmidt E, Schilf A, Tonetti C, Tan Y, Delmas-Marsalet B, Luccioni C, Falissard B and Hoffman RM: Cytotoxic synergism of methioninase in combination with 5-fluorouracil and folinic acid. Biochem Pharmacology 61: 867-876, 2001.
21. Goseki N, Yamazaki S, Shimojyu K, Kando F, Maruyama M, Endo M, Koike M and Takahashi H: Synergistic effect of methionine-depleting total parenteral nutrition with 5-fluorouracil on human gastric cancer: a randomized, prospective clinical trial. Jpn J Cancer Res 86: 484-489, 1995.
22. Poirson-Bichat F, Gonçalves RA, Miccoli L, Dutrillaux B and Poupon MF: Methionine depletion enhances the antitumoral efficacy of cytotoxic agents in drug-resistant human tumor xenografts. Clin Cancer Res 6: 643-653, 2000. (Pubitemid 30111490)
23. TanY, SunX, Xu M, Tan X, Sasson A, Rashidi B, Han Q, Tan X, Wang X, An Z, Sun FX and Hoffman RM: Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice. Clin Cancer Res 5: 2157-2163, 1999.
24. Hoshiya Y, Kubota T, Matsuzaki SW, Kitajima M and Hoffman RM: Methionine starvation modulates the efficacy of cisplatin on human breast cancer in nude mice. Anticancer Res 16: 3515-3517, 1996. (Pubitemid 27085005)
25. Goldberg RM: Advances in the treatment of metastatic colorectal cancer. Oncologist 10: 40-48, 2005.
26. Durando X, Farges MC, Buc E, Abrial C, Petorin-Lesens C, Gillet B, Vasson MP, Pezet D, Chollet P and Thivat E: Dietary methionine restriction with FOLFOX regimen as first line therapy of metastatic colorectal cancer a feasibility study. Oncology, 78: 205-209, 2010.
27. Lishko VK, Lishko OV and Hoffman RM: The preparation of endotoxin-free L-methionine-deamino-mercaptomethane-lyase (L-methioninase) from Pseudomonas putida. Protein Expr Purif 4: 529-533, 1993.
28. Lishko VK, Lishko OV and Hoffman RM: Depletion of serum methionine by methioninase in mice. Anticancer Res 13: 1465-1468, 1993.
29. Hori H, Takabayashi K, Orvis L, Carson DA and Nobori T: Gene cloning and characterization of Pseudomonas putida L-methionine -deamino- -mercaptomethane-lyase. Cancer Res 56: 2116-2122, 1996.
30. Tan Y, Xu M, Tan XZ, Tan XY, Wang X, Saikawa Y, Nagahama T, Sun X, Lenz M and Hoffman RM: Overexpression and large-scale production of recombinant L-methionine-deamino-mercapto-methane-lyase for novel anticancer therapy. Protein Expr Purif 9: 233-245, 1997.
31. Kokkinakis DM, Schold SC Jr, Hori H and Nobori T: Effect of long-term depletion of plasma methionine on the growth and survival of human brain tumor xenografts in athymic mice. Nutr Cancer 29: 195-204, 1997.
32. Kokkinakis DM, Wick JB and Zhou Q-X: Metabolic response of normal and malignant tissue to acute and chronic methionine stress in athymic mice bearing human glial tumor xenografts. Chem Res Toxicol 75: 1472-1479, 2002.
33. Tan Y, Zavala J, Sr, Xu M, Zavala J, Jr. and Hoffman RM: Serum methionine depletion without side-effects by methioninase in metastatic breast cancer patients. Anticancer Res 16: 3937-3942, 1996.
34. Tan Y, Zavala J, Sr, Han Q, Han Q, Xu M, Sun X, Tan X-Z, Tan X-Y, Magana R, Geller J and Hoffman RM: Recombinant methioninase infusion reduces the biochemical endpoint of serum methionine with minimal toxicity in high-stage cancer patients. Anticancer Res 17: 3857-3860, 1997.
35. Yang Z, Wang J, Yoshioka T, Li B, Lu Q, Li S, Sun X, Tan Y, Yagi S, Frenkel EP and Hoffman RM: Pharmacokinetics, methionine depletion, and antigenicity of recombinant methioninase in primates. Clin Cancer Res 10: 2131-2138, 2004.
36. Kozlowski A and Harris JM: Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J Controlled Release 72: 217-224, 2001. (Pubitemid 32522359)
37. Maeda H, Kabanov A, Kataska K and Okano T (eds.). Advances in Experimental Medicine and Biology: Polymer Drugs in the Clinical Stage. Vol. 519, Dordrecht, The Netherlands, Kluwer Academic/Plenum Publishers, 2003.
38. Park CWG and Chuo M: Interferon polymer conjugates. United States Patent 5,951,974, September 14, 1999.
39. Aguayo A, Cortes J, Thomas D, Pierce S, Keating M and Kantarjian H: Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer 86: 1203-1209, 1999.
40. Pool R: "Hairy enzymes" stay in the blood. Science 248: 305, 1990.
41. Hershfield MS: PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin Immunol Immunopathol 76: S228-S232, 1995.
42. Sun X, Yang Z, Li S, Tan Y, Zhang N, Wang X, Yagi S, Yoshioka T, Takimoto A, Mitsushima K, Suginaka A, Frenkel EP and Hoffman RM: In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5′-phosphate supplementation. Cancer Res 63: 8377-8383, 2003.
43. Yang Z, Wang J, Lu Q, Xu J, Kobayashi Y, Takahura T, Takimoto A, Yoshioka T, Lian C, Chen C, Zhang D, Zhang Y, Li S, Sun X, Tan Y, Yagi S, Frenkel EP and Hoffman RM: PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Cancer Res 64: 6673-6678, 2004.
44. Yang Z, Sun X, Li S, Tan Y, Wang X, Zhang N, Yagi S, Takahura T, Kobayashi Y, Takimoto A, Yoshioka T, Suginaka A, Frenkel EP and Hoffman RM: Circulating half-life of PEGylated recombinant methioninase holoenzyme is highly dose dependent on cofactor pyridoxal-5′-phosphate. Cancer Res 64: 5775-5778, 2004.
45. Watanabe N, Kamei S, Ohkubo A, Yamanaka M, Ohsawa S, Makino K and Tokuda K: Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. Clin Chem 32: 1551-1554, 1986. (Pubitemid 17027779)
46. Li S, Yang Z, Sun X, Tan Y, Yagi S and Hoffman RM: A simultaneous colorimetric assay of free and protein-coupled polyethylene glycol. Anal Biochem 313: 335-337, 2003.
47. Takakura T, Takimoto A, Notsu Y, Yoshida H, Ito T, Nagatome H, Ohno M, Kobayashi Y, Yoshioka T, Inagaki K, Yagi S, Hoffman RM and Esaki N: Physicochemical and pharmacokinetic characterization of highly potent recombinant L-methionine γ-lyase conjugated with polyethylene glycol as an antitumor agent. Cancer Res 66: 2807-2814, 2006.
48. Takakura T, Ito T, Yagi S, Notsu Y, Itakura T, Nakamura T, Inagaki K, Esaki N, Hoffman RM and Takimoto A: High-level expression and bulk crystallization of recombinant L-methionine γ-lyase, an anticancer agent. Appl Microbiol Biotechnol 70: 183-192, 2006.
49. TakakuraT, Mitsushima K, Yagi S, Inagaki K, Tanaka H, Esaki N, Soda K and Takimoto A: Assay method for antitumor L-methionine γ-lyase: comprehensive kinetic analysis of the complex reaction with L-methionine. Anal Biochem 327: 233-240, 2004.
50. Diala ES, Cheah MSC, Rowitch D and Hoffman RM: Extent of DNA methylation in human tumor cells. J Natl Cancer Inst 71: 755-764, 1983. (Pubitemid 14232390)
51. Cheah MSC, Wallace CD and Hoffman RM: Hypomethylation of DNA in human cancer cells: a site-specific change in the c-myc oncogene. J Natl Cancer Inst 73: 1057-1065, 1984.
52. Machover D, Zittoun J, Saffroy R, Broet P, Giraudier S, Magnaldo T, Goldschmidt E, Debuire B, Orrico M, Tan Y, Mishal Z, Chevallier O, Tonetti C, Jouault H, Ulusakarya A, Tanguy M-L, Metzger G and Hoffman RM: Treatment of cancer cells with methioninase produces DNA hypomethylation and increases DNA synthesis. Cancer Res 62: 4685-689, 2002.
53. Kudou D, Misaki S, Yamashita M, Tamura T, Takakura T, Yoshioka T, Yagi S, Hoffman RM, Takimoto A, Esaki N and Inagaki K: Structure of the antitumour enzyme L-methionine γ-lyase from Pseudomonas putida at 1.8Å resolution. J Biochem 141: 535-544, 2007.
54. Thivat E, Farges MC, Bacin F, D'Incan M, Mouret-Reynier MA, Cellarier E, Madelmont JC, Vasson MP, Chollet P and Durando X: Phase II trial of the association of a methionine-free diet with cystemustine therapy in melanoma and glioma. Anticancer Res 29(12): 5235-5240, 2009.
55. Durando X, Thivat E, Farges MC, Cellarier E, D'Incan M, Demidem A, Vasson MP, Barthomeuf C and Chollet P: Optimal methionine-free diet duration for nitrourea treatment: a Phase I clinical trial. Nutr Cancer 60: 23-30, 2008.
56. Thivat E, Durando X, Demidem A, Farges MC, Rapp M, Cellarier E, Guenin S, D'Incan M, Vasson MP and Chollet P: A methionine-free diet associated with nitrosourea treatment down-regulates methylguanine-DNA methyl transferase activity in patients with metastatic cancer. Anticancer Res 27(4C): 2779-2784, 2007.